Yaqun Fu, Jingyu Zhao, Peien Han, Jiawei Zhang, Quan Wang, Qingbo Wang, Xia Wei, Li Yang, Tao Ren, Siyan Zhan, Liming Li
{"title":"Cost-effectiveness of COVID-19 vaccination: A systematic review","authors":"Yaqun Fu, Jingyu Zhao, Peien Han, Jiawei Zhang, Quan Wang, Qingbo Wang, Xia Wei, Li Yang, Tao Ren, Siyan Zhan, Liming Li","doi":"10.1111/jebm.12525","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The COVID-19 vaccination strategy has been widely used to protect population health worldwide. This study aims to summarize the cost-effectiveness evidence of economic evaluation of COVID-19 vaccination strategies to provide evidence supporting the usage of COVID-19 vaccination, especially where the supply of COVID-19 vaccine is limited.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic literature review was performed by searching both English and Chinese databases, including PubMed, Embase, Science Direct, Web of Science, Medline, Scopus, and CNKI. Articles published from January 1, 2020 to August 1, 2022 (PROSPERO registration number: CRD42022355442).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 1035 papers identified, a total of 28 English studies that met the preset criteria were included. COVID-19 vaccination and booster vaccination were cost-effective or cost-saving regardless of the vaccine type; vaccine efficacy, vaccine price, vaccine supply or prioritization, and vaccination pace were the influential factors of cost-effectiveness among different population groups. When supply is adequate, mass vaccination should be encouraged, while when supply is inadequate, prioritizing the high risk and the elderly is more cost-effective.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>COVID-19 vaccination strategies are economically favorable in a wide range of countries and population groups, and further research on suitable strategies for booster COVID-19 vaccination is needed.</p>\n </section>\n </div>","PeriodicalId":16090,"journal":{"name":"Journal of Evidence‐Based Medicine","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12525","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Evidence‐Based Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jebm.12525","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 2
Abstract
Objective
The COVID-19 vaccination strategy has been widely used to protect population health worldwide. This study aims to summarize the cost-effectiveness evidence of economic evaluation of COVID-19 vaccination strategies to provide evidence supporting the usage of COVID-19 vaccination, especially where the supply of COVID-19 vaccine is limited.
Methods
A systematic literature review was performed by searching both English and Chinese databases, including PubMed, Embase, Science Direct, Web of Science, Medline, Scopus, and CNKI. Articles published from January 1, 2020 to August 1, 2022 (PROSPERO registration number: CRD42022355442).
Results
Of the 1035 papers identified, a total of 28 English studies that met the preset criteria were included. COVID-19 vaccination and booster vaccination were cost-effective or cost-saving regardless of the vaccine type; vaccine efficacy, vaccine price, vaccine supply or prioritization, and vaccination pace were the influential factors of cost-effectiveness among different population groups. When supply is adequate, mass vaccination should be encouraged, while when supply is inadequate, prioritizing the high risk and the elderly is more cost-effective.
Conclusions
COVID-19 vaccination strategies are economically favorable in a wide range of countries and population groups, and further research on suitable strategies for booster COVID-19 vaccination is needed.
目的COVID-19疫苗接种策略已在世界范围内广泛应用,以保护人群健康。本研究旨在总结COVID-19疫苗接种策略经济评估的成本效益证据,为COVID-19疫苗接种的使用提供证据支持,特别是在COVID-19疫苗供应有限的情况下。方法通过检索PubMed、Embase、Science Direct、Web of Science、Medline、Scopus、CNKI等中英文数据库进行系统文献综述。文章发表于2020年1月1日至2022年8月1日(PROSPERO注册号:CRD42022355442)。结果在1035篇论文中,共纳入了28篇符合预设标准的英语研究。无论疫苗类型如何,COVID-19疫苗接种和加强疫苗接种都具有成本效益或节省成本;影响不同人群成本-效果的因素有疫苗效力、疫苗价格、疫苗供应或优先顺序和接种速度。当供应充足时,应鼓励大规模疫苗接种,而当供应不足时,优先考虑高风险和老年人更具成本效益。结论COVID-19疫苗接种策略在广泛的国家和人群中具有经济效益,需要进一步研究COVID-19加强疫苗接种的合适策略。
期刊介绍:
The Journal of Evidence-Based Medicine (EMB) is an esteemed international healthcare and medical decision-making journal, dedicated to publishing groundbreaking research outcomes in evidence-based decision-making, research, practice, and education. Serving as the official English-language journal of the Cochrane China Centre and West China Hospital of Sichuan University, we eagerly welcome editorials, commentaries, and systematic reviews encompassing various topics such as clinical trials, policy, drug and patient safety, education, and knowledge translation.